BioSapien is pioneering a localized cancer treatment technology known as MediChip™, which is designed to deliver medication directly to tumor sites. This innovative approach utilizes a small, bio-compatible patch that can be attached to any tissue, allowing for targeted drug delivery. MediChip™ can accommodate multiple drug combinations, enhancing its effectiveness in shrinking tumors, alleviating symptoms, and potentially improving surgical outcomes. By focusing treatment directly on the tumor, this technology aims to significantly reduce the harsh side effects commonly associated with systemic chemotherapy, thereby improving the overall quality of life for patients undergoing cancer treatment.

The MediChip™ technology represents a significant advancement in cancer care, with the potential to address a wide range of lower gastrointestinal and solid tumors globally. BioSapien has secured global patents for this platform, ensuring its protection and future development until 2039. The company has garnered support from leading cancer and surgery specialists at prestigious institutions, highlighting its credibility and the promise of its innovative therapies. With substantial funding from various investors, BioSapien is well-positioned to transform patient care and contribute to the ongoing fight against cancer.

United States

Biosapien is a late-stage pre clinical company focused on novel drug delivery platforms.

BioSapien

Company Details